Sagimet Biosciences Inc. SGMT
Sagimet Biosciences Inc. (Nasdaq: SGMT) is a GI/hepatology drug developer. Its lead program, denifanstat (TVB-2640), is in Phase 2 for MASH (also acne and select cancers). Its next catalyst on record is Denifanstat-resmetirom combination: Denifanstat-resmetirom combination Phase 2 readiness expected by end of 2026. (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Denifanstat-resmetirom combination — Denifanstat-resmetirom combination Phase 2 readiness expected by end of 2026. (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| denifanstat | MASH (Phase 2b FASCINATE-2 complete; further MASH development paused pending non-dilutive financing) | small molecule | Phase 2 |
| denifanstat + resmetirom | cirrhotic MASH (F4) | small molecule | Phase 1 |
| TVB-3567 | acne | small molecule | Phase 1 |
Recent results and decisions
- Oct 22, 2026positive Dosing for SAD/MAD and food effect parts complete for TVB-3567; drug was generally well tolerated and Phase 2 doses identified.
Dosing for SAD/MAD and food effect parts complete, TVB-3567 was generally well tolerated Phase 2 doses have been identified
Filing - Oct 22, 2026met Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial (ASC40-303) in patients with moderate to severe acne vulgaris in China.
Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in patients with moderate to severe acne vulgaris in China
Filing - Oct 22, 2026positive Dosing for SAD/MAD and food effect parts of TVB-3567 Phase 1 clinical trial complete; TVB-3567 was generally well tolerated.
Dosing for SAD/MAD and food effect parts complete, TVB-3567 was generally well tolerated; Phase 2 doses have been identified
Filing
10 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.